Treace Announces Interim 3-Year ALIGN3D™ Clinical Study Data at the 2024 ACFAS Scientific Conference Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure

February 2, 2024

https://www.globenewswire.com/news-release/2024/02/02/2822994/0/en/Treace-Announces-Interim-3-Year-ALIGN3D-Clinical-Study-Data-at-the-2024-ACFAS-Scientific-Conference-Demonstrating-Sustained-Positive-Outcomes-of-the-Lapiplasty-Procedure.html

PONTE VEDRA, Fla., Feb. 02, 2024 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced three-year interim clinical data from its ALIGN3D™ post-market study supporting the use of the Lapiplasty® procedure for treating bunions were presented in a podium presentation at the 2024 American College of Foot and Ankle Surgeons (“ACFAS”) Annual Scientific Conference.

Read more at globenewswire.com

Related news for (TMCI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.